Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Data on cancer gene therapy described by researchers at University of Texas, Department of Cell Biology
March 2nd, 2007
Investigators publish new data in the report "Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. We determined previously that a novel human telomerase RNA (hTR) antagonist, GRN163L, inhibited the tumorigenic potential of A549-luciferase (A549-luc) lung cancer cells in vitro and in vivo. Further studies revealed that A549-luc cells were also morphologically altered by GRN163L," scientists in the United States report. "A549-luc cells treated before cell attachment with a single dose of GRN163L only weakly attached to the substrate and remained rounded, whereas control mismatch-treated cells exhibited typical...
Source: Drug Week (2007-03-02)
|
